# Johnson & Johnson (JNJ) — Q4-2023 Earnings Results

**Report date:** 2024-01-23 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2023

## Post-Earnings Brief

### Headline

Johnson & Johnson Beats on EPS, Stock Reaction Not Available

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.29 | N/A | +0.97% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed cautious optimism about the company's performance and future prospects. They noted the importance of innovation and strategic investments.

**Key quotes:**

> Management highlighted strong performance in key segments despite market challenges.

> They emphasized ongoing investments in innovation and product development.

> The company remains focused on long-term growth strategies.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

This earnings report shows that Johnson & Johnson was able to exceed expectations on EPS, indicating some resilience in its operations. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors will be watching closely for any updates on strategic initiatives and market conditions.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2023_